

ORIGINAL ARTICLE

Liraglutide in a real-world setting: Joint modeling of metabolic response, prediction of efficacy, and cardiovascular risk



Isabel Alonso-Troncoso^{a,*}, Carmen Carollo-Limeres^b, Mónica Rios-Prego^c, Ipek Guler^b, Carmen Cadarso-Suárez^b, Alexis F-Mariño^d

^a Servicio Endocrinología, Complejo Hospitalario Universitario de Pontevedra, Spain

^b Unidad de Bioestadística, Facultad de Medicina, Universidad Santiago de Compostela, Santiago de Compostela, Spain

^c Servicio Medicina Interna, Complejo Hospitalario Universitario de Pontevedra, Spain

^d Servicio Endocrinología, Complejo Hospitalario Universitario de Vigo, Spain

Received 28 June 2018; accepted 7 September 2018

Available online 6 December 2018

KEYWORDS

Type 2 diabetes mellitus;
Liraglutide;
Efficacy;
Real-world studies;
Cardiovascular risk

Abstract

Introduction and objectives: The worldwide prevalence of type 2 diabetes mellitus increases in parallel to that of obesity. Liraglutide (LRG), a glucagon-like peptide-1 receptor agonist, can reduce body weight. This study assessed the metabolic efficacy of LRG in real-world clinical practice.

Methods: An observational, retrospective cohort study including patients treated with LRG for at least one year (187 patients). Anthropometric and metabolic variables, a composite endpoint, factors predicting response to LRG, and cardiovascular risk over time were assessed. A linear mixed-effects model with a bivariate structure was constructed to investigate the time-dependent relationship between weight and HbA1c values.

Results: HbA1c levels and weight significantly decreased in the first 12 weeks, and the decrease persisted at 12 and 24 months in all subgroups studied. Mean weight and HbA1c decreases after 24 months were 8.5 kg and 1.7% respectively. HbA1c values <7% were achieved by 42% of patients at 12 months and by 40% at 24 months. Treatment with LRG allowed for reduction in insulin dose. No serious adverse events were noted. Cardiovascular risk decreased from high to moderate-low.

Abbreviations: T2DM, type 2 diabetes mellitus; LRG, liraglutide; GLP1-RA, GLP1 receptor agonist; % EBML, percentage of excess BMI lost.

Abreviaturas: T2DM, diabetes M tipo 2; LRG, liraglutide; GLP1-RA, agonista del receptor del GLP1; % EBML, porcentaje pérdida de exceso IMC.

* Corresponding author.

E-mail address: ialonsot61@gmail.com (I. Alonso-Troncoso).

<https://doi.org/10.1016/j.endinu.2018.09.005>

2530-0164/© 2018 SEEN y SED. Published by Elsevier España, S.L.U. All rights reserved.

PALABRAS CLAVE

Diabetes mellitus tipo 2;
Liraglutida;
Eficacia;
Estudios en vida real;
Riesgo cardiovascular

Conclusions: Under standard clinical practice conditions, LRG achieved a better metabolic response than seen in clinical trials. Efficacy at 12 weeks of treatment is a good predictor of response. LRG allows for delaying or reducing insulin dose by improving both weight and glucose control. Cardiovascular risk improved.

© 2018 SEEN y SED. Published by Elsevier España, S.L.U. All rights reserved.

Liraglutida en vida real: modelización conjunta de la respuesta metabólica, predicción de eficacia y riesgo cardiovascular

Resumen

Introducción y objetivos: La prevalencia mundial de diabetes mellitus tipo 2 aumenta junto a la de la obesidad. Liraglutida (LRG), un agonista del receptor del péptido similar al GLP1, es un fármaco antidiabético capaz de reducir peso. Evaluamos en práctica clínica de vida real su eficacia metabólica.

Método: Estudio de cohorte observacional retrospectivo. Se incluyeron los pacientes tratados al menos durante un año con LRG (187 pacientes). Evaluamos variables antropométricas, metabólicas, objetivos combinados, factores predictivos de respuesta y evolución del riesgo cardiovascular. Se construyó un modelo de efectos mixtos lineales de estructura bivariante para investigar la relación tiempo-dependiente entre el peso y los valores de HbA1c.

Resultados: Descenso significativo de los valores de HbA1c y peso en las primeras 12 semanas de tratamiento, mantenido a los 12 y 24 meses, en todos los subgrupos estudiados. Reducción media de peso y HbA1c tras 24 meses de tratamiento de 8,5 kg y 1,7%. El valor de HbA1c fue <7% en 42% de pacientes a los 12 meses, 40% a los 24 meses. El tratamiento con LRG permitió reducir la dosis de insulina. No registramos eventos adversos graves. El riesgo cardiovascular mejoró.

Conclusiones: Bajo condiciones de práctica clínica habitual la respuesta metabólica a LRG resultó mejor que la observada en ensayos clínicos. La eficacia a las 12 semanas de tratamiento es un buen predictor de respuesta. LRG permite retrasar o reducir la insulinoterapia. Los pacientes mejoraron su riesgo cardiovascular.

© 2018 SEEN y SED. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Introduction

Type 2 diabetes mellitus (T2DM) affects people throughout the world. Its prevalence has been increasing dramatically as a result of aging populations and the rising prevalence of obesity.^{1,2}

Insulin resistance is an underlying cause of T2DM and is associated with obesity. Consequently, weight reduction is a key goal of treatment. Whenever possible, medications should be chosen to promote weight loss.

Weight gain can offset the beneficial effects of good glycemic control and discourage patients from adhering to treatment. Even moderate weight loss has been shown to improve glycemic control.^{3,4} Guidelines^{3,5,6} recommend a patient-centered approach.

The safety and efficacy profile of the GLP1-RA liraglutide (LRG) has been evaluated in clinical trials,^{7,8} which have shown that, in addition to controlling glycemia, LRG can reduce body weight. A meta-analysis⁹ evaluating the results of head-to-head trials showed LRG to be one of the most effective drugs for control of glycemia and obesity.

Conditions affecting people with T2DM (hypertension, dyslipidemia, obesity, physical inactivity) increase the risk of

heart disease. LRG¹⁰ and empagliflozin¹¹ reduce cardiovascular and all-cause mortality when added to standard care in clinical trials. Ongoing studies are investigating the cardiovascular benefits of other agents in these drug classes. Real-world and post-marketing studies are being promoted to provide data that will help clinicians to choose appropriate options and corroborate safety.

The primary objective of the present study was to evaluate the metabolic effectiveness and safety of LRG in T2DM patients in real-world clinical practice over a longer period than during clinical trials. The secondary objectives were to evaluate potential clinical predictors of response, effectiveness of LRG in various patient subgroups, and changes in cardiovascular risk. A special analysis of patients receiving insulin treatment was performed.

Methods**Study design**

We performed a 1-year observational, retrospective cohort study (October 2015 to October 2016). We identified patients

treated with LRG according to the indications of usual clinical practice.¹²

The study was approved by the Ethics Committee of the Galician Health Service (SERGAS) and conducted according to the requirements of the Declaration of Helsinki and the principles of Good Clinical Practice.

Patients

The study population comprised outpatients followed under conditions of routine clinical practice. The inclusion criteria were T2DM, age ≥ 18 years, and body mass index (BMI) ≥ 30 kg/m².

Study variables

The variables we recorded at baseline were sex, age, diabetes duration, cardiovascular risk factors (hypertension, dyslipidemia, smoking, general vascular disease, sleep apnea syndrome), and previous treatment (metformin, combined oral antidiabetic drugs, insulin).

The parameters evaluated during follow-up (at 3, 6, 12, 18, 24, 30, and 36 months) were body weight, BMI, percentage of excess BMI lost (% EBML), HbA1c, fasting blood glucose, systolic and diastolic blood pressure, and lipid profile.

We also evaluated the proportion of patients achieving an HbA1C target of <7% and a composite endpoint (CEP), which was defined as follows:

- CEP I: HbA1c reduction ≥ 1 and weight loss $\geq 5\%$
- CEP II: HbA1c reduction ≥ 1 and weight loss $\geq 3\%$
- CEP III: HbA1c reduction ≥ 0.4 and weight loss $\geq 5\%$
- CEP IV: HbA1c reduction ≥ 0.4 and weight loss $\geq 3\%$
- CEP V: HbA1c reduction ≥ 0.4 and no weight increase or weight loss >3% with no increase in HbA1c

We evaluated baseline characteristics that could be predictive of response to LRG. We analyzed response (HbA1C, weight) by subgroups: age, sex, diabetes duration, treatment at baseline. Patients who were receiving insulin were evaluated to study the effect of adding LRG.

We evaluated the risk of cardiovascular disease using Regicor Calculator, which is adapted to the Spanish population.¹³

Statistical analysis

A linear mixed-effects model¹⁴ was used to study the overall reduction in weight and HbA1c during treatment. The model enables us to study the effect of time and duration of diabetes flexibly using a quadratic function to determine whether the responses are linear or not over time.

The linear mixed effects model is constructed with a bivariate structure to investigate the time-dependent relationship between weight and HbA1c values. We used the bivariate longitudinal analysis introduced by Thiébaud et al.,¹⁵ which enables testing of the difference between the longitudinal outcomes and joint testing of a treatment effect on a set of outcomes.

The statistical analysis was performed using R, Version 2.12.0 (R Development Core Team, Vienna, Austria) and SAS, Version 9.2 (SAS Institute Inc., Cary, North Carolina, USA). Statistical significance was set at $p < 0.05$.

Results

Baseline sample

The study population comprised 209 patients. Twenty-two were withdrawn. Metabolic response was evaluated in the remaining 187 cases. Of these, 171 patients completed 12 months on treatment (Group A), 85 completed 24 months (Group B), and 20 completed 36 months (Group C).

The reasons for withdrawal were LRG-related adverse events (13 cases), death (5 cases), acute complications (2 cases), and lost cases (2 cases).

LRG was discontinued in 34 cases (18%) owing to lack of efficacy, which the physician considered as inadequate glycemic and/or weight response according to his individualized objectives. Most of them discontinued treatment between 3 and 6 months from the start. These patients were considered for the effectiveness evaluation.

We evaluated the descriptive baseline characteristics of the basal 187 patients (Table 1).

Table 1 Baseline characteristics ($n = 187$).

Characteristic	<i>n</i> (%)
Sex	
Female	104 (56%)
Male	83 (44%)
Age mean \pm SD	58.4 \pm 10.3
≤ 50 years	39 (21%)
51–65 years	100 (53%)
>65 years	48 (26%)
Diabetes duration	7.1 \pm 6.5
<5 years	83 (44%)
5–10 years	53 (28%)
>10 years	51 (27%)
Previous treatment	
Metformin	32 (17%)
Combined OAD ^a	92 (49%)
Insulin	59 (32%)
Fasting plasma glucose, mg/dL	208.7 \pm 72.8
HbA1c %	8.6 \pm 1.9
BMI kg/m²	39.2 \pm 6.0
Weight kg	103.2 \pm 17.8
Abdominal circumference cm	121.8 \pm 11.1
SAS	27 (15%)
Smokers	32 (17%)
CVD	37 (20%)

CVD: cardiovascular disease; HbA1c: glycated hemoglobin A1c; ND: no data; SAS: sleep apnea syndrome; SD: standard deviation.

^a Combined oral antidiabetic drugs: metformin, sulfonylureas, pioglitazone. Patients on sodium-glucose cotransporter 2 inhibitors (SGLT2i) were not included.




Figure 1 Effect of LRG treatment on HbA1c (A) and body weight (B) over time (mean) for patients in treatment for 12 months (n 171) and 24 months (n 85).

Metabolic response

Overall, the mean reduction in weight was 8.6 kg at 12 months, 8.5 kg at 24 months, and 9 kg at 36 months. The mean reduction in HbA1c was 1.7% at 12 months, 24 months, and 36 months. A significant reduction in HbA1c (Fig. 1A) and weight (Fig. 1B) was observed as early as week 12, and this was maintained at 12 and 24 months.

Table 2 shows the progress of metabolic variables for patients who had received treatment for 12 months, 24 months, and 36 months. We found a marked and stable improvement over time in most of the metabolic parameters analyzed.

HbA1c <7% was achieved by 42% of patients at 12 months and by 40% at 24 months. The results at 12–24 months for each of the CEP defined (see Material and Methods, Study variables) were as follows: CEP I, 34%–36%; CEP II, 39%–44%; CEP III, 49%–48%; CEP IV, 59%–57%; and CEP V, 74%–79%. There were no differences between sexes. The results for HbA1c compared with changes in body weight from baseline to 12 and 24 months are shown in Fig. 2 (scatterplot). Most patients achieved a reduction in both parameters.

Correlation between metabolic response and study variables

We evaluated HbA1c over time (at 12/24 months) according to age, diabetes duration, baseline antidiabetic medication and sex. With respect to age, the variation was as follows: <50 years, $-2.3\%/ -1.68\%$; 51–65 years, $-1.3\%/ -1.2\%$; >65 years, $-1.3\%/ -1.5\%$. According to duration of diabetes: <5 years, $-1.7\%/ -1.5\%$; 5–10 years, $-1.5\%/ -1.2\%$; >10 years, $-1.2\%/ -1.1\%$ and baseline antidiabetic medication: metformin, $-1.7\%/ -1.5\%$; oral agents, $-1.6\%/ -1.2\%$; insulin, $-1.4\%/ -1.5\%$. According to sex: female, $-1.5\%/ -1.4\%$; male $-1.56\%/ -1.3\%$.

The decrease in HbA1c was significant in all the subgroups, although there were no significant differences between the subgroups.

Statistical correlation studies results are shown at Table 3. The results of the bivariate linear mixed effects model (weight and HbA1c) are shown in Table 3A. No

correlations were found between reduction in weight and HbA1c with respect to age or sex. According to the baseline BMI value, the reduction in HbA1c was inversely correlated with BMI, although weight reduction was not. Therefore, LRG reduced BMI equally well at all baseline BMI values. However, the decrease in HbA1c was lower with a higher baseline BMI.

The HbA1c reduction was inversely correlated with duration of diabetes, although weight reduction was not. The relationship was linear, that is, the lower the duration of diabetes, the greater the reduction in HbA1c.

The correlation of the random intercept and slopes for the reduction in weight and HbA1c was obtained based on a longitudinal multivariate model (Table 3B). The intercept represents the correlation between the baseline measurements; the slope represents the time-dependent correlation between weight and HbA1c. The model therefore indicated that the greater the initial BMI, the lower the decrease in the HbA1c slope, and the higher the initial HbA1c, the greater the decrease in the slope of HbA1c.

The duration of therapy with LRG was directly correlated with the decrease in weight and HbA1c as a result of the initial and early response that was maintained over time. In this case, the relationship was quadratic, not linear (Fig. 1A and B).

Effect of adding LRG to previous insulin treatment

Of the 68 patients (36%) receiving insulin at baseline (0.55 ± 0.4 IU/kg), 59 patients were evaluated at 12 months and 23 (39%) had stopped insulin. Of the 30 patients evaluated at 24 months, 8 (26%) had stopped insulin. The patients who continued to take insulin reduced their dose to 0.41 ± 0.2 IU/kg at 12 months and to 0.43 ± 0.2 IU/kg at 24 months.

In patients receiving insulin, baseline HbA1c fell from 9.5 ± 1.8 to $9.3 \pm 1.7\%$ at 12 months ($n=36$) and to $8.9 \pm 1.3\%$ at 24 months. In the subgroup of patients who stopped insulin, baseline HbA1c fell to $7.2 \pm 1.4\%$ ($n=23$) at 12 months and to $7.7 \pm 1.5\%$ ($n=8$) at 24 months. A significant reduction in weight was observed: from 98.1 ± 15.6 kg to 89.5 ± 15.5 kg at 12 months and 88.2 ± 13.9 kg at 24 months.

Table 2 Evolution of metabolic variables according to the group studied: Group A (n 171) patients treated for 12 months, Group B (n 85) patients treated for 24 months and Group C (n 20) patients treated for 36 months.

Metabolic variable	Time in LRG treatment			
	0	12 months	24 months	36 months
Mean±SD (change with respect to basal value)				
<i>Weight, kg</i>				
Group A	102.8 ± 17.8	95.4 ± 17.4 (-7.4 ± 6.5)		
Group B	102.6 ± 19.1	94.7 ± 18.4 (-7.9 ± 6.7)	95.1 ± 18 (-7.5 ± 6.3)	
Group C	108.2 ± 17.8	97.8 ± 17 (-10.4 ± 9.7)	98.8 ± 17.8 (-9.4 ± 8.7)	99.2 ± 19.3 (-9 ± 9.1)
<i>HbA1c, %</i>				
Group A	8.7 ± 1.9	7.3 ± 1.8 (-1.4 ± 1.7)		
Group B	8.9 ± 1.8	7.3 ± 1.8 (-1.6 ± 2)	7.5 ± 1.7 (-1.4 ± 1.5)	
Group C	8.9 ± 1.8	6.8 ± 1.4 (-2.1 ± 2.8)	7 ± 1.2 (-1.9 ± 2.7)	7.2 ± 1.4 (-1.7 ± 1.5)
<i>BMI, kg/m²</i>				
Group A	39.2 ± 6	36.3 ± 5.6 (-2.9)		
Group B	38.9 ± 5.8	35.8 ± 5.2 (-3.1)	36 ± 5.6 (-2.4)	
Group C	40.4 ± 6	36.6 ± 5 (-3.8)	36.9 ± 5.2 (-3.5)	37.1 ± 5.7 (-3.3)
<i>SBP, mmHg</i>				
Group A	154.2 ± 23.6	140.3 ± 18.8 (-13.9)		
Group B	154.4 ± 25.6	139.7 ± 18.1 (-14.7)	138.1 ± 17.7 (-16.3)	
Group C	160 ± 19.7	140.5 ± 17.7 (-19.5)	144.5 ± 21.4 (-15.5)	135.5 ± 12 (-25)
<i>DBP, mmHg</i>				
Group A	85.4 ± 14.2	79.6 ± 11.9 (-5.8)		
Group B	85.9 ± 15.2	77.8 ± 10.9 (-8.1)	78.7 ± 12.7 (-7.2)	
Group C	91 ± 12.9	78.3 ± 13.4 (-12.7)	79.8 ± 14.3 (-11.2)	79 ± 10.7 (-12)
<i>Basal glucose, mg/dL</i>				
Group A	214.3 ± 72.2	157.6 ± 60.1 (-56.7)		
Group B	224.5 ± 69.3	154.7 ± 56.5 (-69.8)	164.4 ± 62.2 (-60.1)	
Group C	235 ± 69.2	146.2 ± 54.4 (-89)	150.9 ± 43.8 (-84)	176.1 ± 70.4 (-59)
<i>Cholesterol, mg/dL</i>				
Group A	200.3 ± 42.4	184.6 ± 43.3 (-15.7)		
Group B	202.9 ± 39.7	187.2 ± 49.6 (-15.7)	183.6 ± 35.9 (-19.3)	
Group C	224.7 ± 42.2	192.5 ± 41.7 (-32.2)	177.8 ± 35.9 (-46.9)	196.6 ± 47 (-28.1)
<i>HDL-C, mg/dL</i>				
Group A	49 ± 12.4	50.7 ± 11.9 (+1.7)		
Group B	48.7 ± 12.2	51.3 ± 12.4 (+2.6)	48.4 ± 10.2 (-0.3)	
Group C	46.1 ± 10.1	53.1 ± 14.5 (+7)	47.6 ± 10.4 (+1.5)	46.9 ± 10.3 (+0.8)
<i>LDL-C, mg/dL</i>				
Group A	108.5 ± 38.6	99.9 ± 40.3 (-8.6)		
Group B	107.3 ± 37.5	102.6 ± 45.7 (-4.7)	99.7 ± 32.8 (-7.6)	
Group C	134.0 ± 44.3	106.7 ± 35.9 (-27.3)	97.4 ± 36.2 (-36.6)	46.7 ± 10.5 (-87.3)
<i>Triglycerides, mg/dL</i>				
Group A	229.6 ± 144.4	180.2 ± 89.4 (-49.4)		
Group B	245.7 ± 136.5	171.7 ± 70.8 (-74)	186.1 ± 97.1 (-59.6)	
Group C	252.7 ± 121.1	173.7 ± 64.6 (-79)	182.9 ± 11.7 (-69.8)	187.4 ± 86.6 (-65.3)

BMI: body mass index; DBP: diastolic blood pressure; HbA1c: glycated hemoglobin A1c; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; SBP: systolic blood pressure.

Evaluation of %EBMIL with LRG treatment

EBMIL is the criterion used to evaluate metabolic surgery, which was considered successful (EBMIL >50%) in 15 patients (9%) at 12 months and in 7 patients (8%) at 24 months. EBMIL was >10% in 125 patients (73%) at 12 months and in 65 patients (77%) at 24 months.

Adverse events

No serious adverse events were observed. Thirteen patients stopped treatment because of digestive intolerance (nausea and vomiting 7 cases, diarrhea 4 cases, and increased amylase 2 cases). No patients had pancreatitis or pancreatic cancer. Five patients died (cancer of the liver, lung,




Figure 2 Scatter plot of changes in body weight and HbA1c from baseline to 12 and 24 months after LRG introduction.

colon, bladder, and genitals). Acute complications (major intercurrent process or adverse event not related to LRG) were observed in 2 cases (ACVA and appendicitis).

Cardiovascular risk during treatment with LRG

Cardiovascular risk evolution was evaluated using REGICOR.¹³ Patients on LRG treatment for 12 months: at baseline at very high risk was 14 (10%) it decreased to 5 (3%) at 12 months; 38 (26%) patients at high risk decreased

to 17 (12%) at 12 months; 58 (40%) patients at moderate risk increased to 71 (49%) and 34 (24%) patients at low risk increased to 51 (35%) at 12 months.

Patients on LRG treatment for 24 months: at baseline at very high risk was 7 (8%) it decreased to 3 (4%) at 24 months; 24 (30%) patients at high risk decreased to 15 (19%) at 24 months; 30 (38%) patients at moderate risk increased to 33 (41%) and 19 (24%) patients at low risk increased to 29 (36%) at 24 months. Treatment with LRG for 12–24 months, combined with other treatments used in real-world practice, reduced cardiovascular risk from high to moderate-low.

Discussion

We performed a retrospective observational cohort study to evaluate the metabolic effectiveness and safety of LRG in patients with T2DM in real-world clinical practice over a longer period than that usually assessed in clinical trials. We found that therapy with LRG reduced weight at 12, 24, and 36 months. Hb1Ac also decreased to target in almost half of the study population at 12 and 24 months. Most patients achieved the composite endpoint. Adding LRG to basal insulin treatment enabled nearly one-third of patients to stop insulin; the remainder were able to reduce their dose by one-third and weight reduction was significant.

In a recent review of 124 publications,¹⁶ HbA1c was significantly reduced after 6 months of treatment with LRG (mean change from baseline 0.9%–2.2%; HbA1c <7.0%, 29.5–65.0%). The NICE composite endpoint (HbA1c reduction ≥1% and weight loss ≥3%) was met in 16.9–47.0% of cases, and the absolute weight change was –1.3 to –8.65 kg. Our results were consistent with the best of these, even though the time on treatment with LRG was longer than most of them.

Table 3A Results of the bivariate linear mixed effects model.

	Weight reduction model		HbA1c reduction model	
	Coeff (SD)	p value	Coeff (SD)	p value
Intercept	5.31 (2.71)	0.05	3.09 (0.97)	<0.01
Age	–0.04 (0.02)	0.08	0.002 (0.01)	0.77
Male sex	–0.84 (0.58)	0.14	–0.22 (0.20)	0.28
BMI	0.08 (0.05)	0.10	–0.04 (0.01)	0.02
Treatment time	0.21 (0.03)	<0.01	0.03 (0.01)	<0.01
Treatment time ²	–0.005 (0.001)	<0.01	–0.0009 (0.0003)	<0.01
Duration of diabetes	–0.16 (0.11)	0.17	–0.08 (0.04)	0.03
Duration of diabetes ²	0.007 (0.004)	0.09	0.001 (0.001)	0.46

SD: standard deviation. Treatment time² and duration of diabetes² are a quadratic effect of treatment time and duration of diabetes, respectively. These variables capture the non-linear effect of the corresponding outcomes.

Table 3B Intercept and slopes for reduction in weight and HbA1c.

	Intercept weight reduction	Intercept HbA1c reduction	Slope weight reduction	Slope HbA1c reduction
Intercept weight	1	0.02	–0.13	0.42
Intercept HbA1c	0.02	1	–0.15	–0.24
Slope weight	–0.13	–0.15	1	0.12

When our results were compared with those of EVIDENCE,¹⁷ the most longer (24 months) and big population sample (n 2019) in this review, the greater mean HbA1c and weight reduction in our series can be explained by the shorter duration of diabetes and higher initial weight.

This review includes three Spanish studies; Gomez Peralta et al.¹⁸ reported a 4.4 kg reduction at 3 months (n 158); Diaz-Soto G et al.,¹⁹ a 0.9% HbA1c reduction at 4 months (n 59) and Mezquita-Raya et al.,²⁰ a 1.1% HbA1c and 4.6 kg reduction at 6 months of LRG treatment.

Later Lecube et al.²¹ reported a HbA1c decrease near 1.2% and weight loss 7.3 kg during 6 months treatment.

A recent multicentric publication in Spain²² (24 months treatment) reports a HbA1c reduction ranging from 1.0% to 1.5% and body weight from 5 kg to 10 kg.

We found that the metabolic response was early (3–6 months) and maintained over time. This finding could be explained by the appropriate selection of responders in our real-world setting.

Evaluation of the reduction in HbA1c using the random intercept and slope model revealed a correlation with the baseline value (the higher the baseline value, the greater the reduction). In contrast, the reduction and intercept for the HbA1c slope were lower at higher BMI levels, probably because LRG was indicated for patients with relatively low baseline HbA1c and very high baseline BMI, with correction of high BMI being the main objective of therapy with LRG in this subgroup. Given the findings for baseline BMI and the subsequent reduction therefore, treatment with LRG reduced BMI equally well across all baseline BMI values. Consequently, the effect of LRG on weight could be independent of the effect on HbA1c. This result supports the indication of LRG for weight reduction.

The reduction in HbA1c was inversely correlated with duration of diabetes. The relationship was linear, that is, the lower the duration of diabetes, the greater the reduction in HbA1c. In contrast, no correlation was observed for the reduction in weight; the effect of therapy on weight was independent of duration of diabetes. These findings also support an independent effect of LRG on glycemia and on weight.

Treatment of diabetes and obesity should be intensified once the diagnosis has been confirmed, and every opportunity should be taken to create a legacy effect.^{23–25} The efficacy and maintained effect of LRG over time make it a promising option when attempting to create a legacy effect in obese patients with diabetes.

The decrease in weight and HbA1c was more pronounced as the time on LRG increased. However, this finding can be explained by the initial and early response, which was maintained over time. The statistical analysis showed that the initial glycemia and weight responses were based on a quadratic model and not on a linear model, thus confirming these early responses as major predictive markers of response to LRG.

Given that the effects of therapy with LRG were clear after 12 weeks, a 3-month trial period may be sufficient to demonstrate the potential of the drug to reduce both weight and HbA1c. Treatment could be discontinued in patients who do not respond within this period.

Addition of LRG to insulin has proven to be effective in reversing weight gain, decreasing the insulin dose, and

improving glycemic control in obese patients.²⁶ The results of the subgroup of patients who were taking insulin at baseline are particularly interesting. Some were able to stop or reduce insulin dose, and both weight and Hb1Ac improved considerably. Consequently, in obese patients with T2DM, treatment with GLP1-RA should be considered before starting with insulin^{3,5,6} or uptitrating its dose. We may be able to “rescue” patients who received intensive therapy with insulin before LRG was marketed. Our results of combined LRG and insulin therapy may help to understand the results of previous studies.²²

Evaluation of the EBML enabled us to compare our results with those obtained with bariatric surgery.^{27,28} Our results suggest that LRG treatment in T2DM obese patients could facilitate or even eliminate the need for surgery in patients who could reach the target %EBML with LRG alone.

Most adverse effects involved the gastrointestinal tract and were mild. These were less frequent than in clinical trials.⁷ The favorable safety profile of LRG could facilitate adherence to dietary modifications and ensure continued health benefits over time.

Recent trials evaluating LRG,¹⁰ empagliflozin,¹¹ semaglutide,²⁹ canagliflozin³⁰ showed improved cardiovascular outcomes in patients with T2DM. The mechanism underlying these results and the question of whether outcome was a class effect or not remain open to debate. Our results for cardiovascular risk are consistent with those of the LEADER trial.¹⁰ In our study, we cannot attribute the improvement in cardiovascular risk exclusively to LRG. The treatment schedule was multifactorial, as recommended in guidelines. The addition of LRG could enable high-risk patients to be reclassified as moderate-low risk.

This study has limitations mainly related to its observational retrospective design. The criterion to define lack of efficacy and discontinue LRG treatment was not predefined, it was individualized decided by the physician. We must consider the influence of confounding factors. The combined antidiabetic therapy prescribed did not include SGLT2i. Future results of metabolic effectiveness studies in real-world clinical practice including combined SGLT2i and GLP1-RA may be compared with our results just using GLP-RA.

Real-world data have the potential to improve the quality and delivery of medical care, reduce overall costs, and improve outcomes by accelerating our understanding of how best to incorporate new therapies into everyday clinical practice. Such data help to fill the knowledge gap between clinical trials and actual clinical practice.

Conclusions

In conclusion, we found that therapy with LRG under conditions of routine clinical practice produced a better metabolic response (weight loss and reduction in Hb1Ac) than that observed in clinical trials. The early effect observed in responders at 3 months was maintained at 12 and 24 months and was the best predictor of response to LRG. The weight response was independent of baseline BMI, baseline HbA1c, and duration of diabetes. The HbA1c response was greater when baseline HbA1c was higher and duration of diabetes was shorter. LRG could delay or reduce the

insulin dose in a significant subgroup of obese patients by improving weight simultaneously with glycemic control. We also observed an improvement in cardiovascular risk factors enabling patients to be transferred from the high-risk category to medium-low risk. Consequently, LRG would be a suitable candidate for inclusion in multifactorial interventions aimed at reducing the risk of cardiovascular events.

Founding sources

Medical writing, editorial assistance (Cociente, S.L.), and the statistical analysis were funded by a grant from Novo Nordisk. The authors take full responsibility for the content and conclusions stated in this manuscript. Novo Nordisk neither influenced the content of this publication nor was involved in the study design or in the collection, analysis, or interpretation of the data reported.

Conflict of interests

The authors declare no conflict of interests.

References

1. Maps of trends in diagnosed diabetes and obesity, April 2017; CDC's Division of Diabetes Translation. United States Diabetes Surveillance System. https://www.cdc.gov/diabetes/statistics/slides/maps_diabetesobesity94.pdf (accessed 20.06.18).
2. Abarca-Gómez L, Abdeen ZA, Hamid ZA, Abu-Rmeileh NM, Acosta-Cazares B, Acuin C, et al. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. *Lancet*. 2017;390:2627–42.
3. Standards of medical care in diabetes – 2018. *Diabetes Care*. 2018; 41. Suppl. 1-159.
4. Heymsfield SB, Wadden TA. Mechanisms pathophysiology, and management of obesity. *N Engl J Med*. 2017;376:254–66.
5. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus statement by the American College of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2018 executive summary. *Endocr Pract*. 2018;24:91–120.
6. Documento de Abordaje integral de la Diabetes Tipo 2. Grupo de trabajo de diabetes Mellitus de la Sociedad Española de Endocrinología y Nutrición. de la http://www.seen.es/docs/apartados/355/2018%2005%2005%20Abordaje%20Integral%20DM2..SEEN.2018_GTDMSEEN%201.pdf [accessed 15.08.18].
7. Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. *Diabetes Obes Metab*. 2009;11 Suppl. 3:26–34.
8. Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes Randomized Clinical Trial. *JAMA*. 2015;314:687–99.
9. Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. *Ther Adv Endocrinol Metab*. 2015;6:19–28.
10. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2016;375:311–22.
11. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med*. 2015;373:2117–28.
12. <http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001026/human.med.001137.jsp&mid=WC0b01ac058001d124> [accessed 20.06.18].
13. Marrugat J, Solanas P, D'Agostino R, Sullivan L, Ordovas J, Cordón F, et al. Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada. *Rev Esp Cardiol*. 2003;56:253–61.
14. Laird NM, Ware JH. Random-effects models for longitudinal data. *Biometrics*. 1982;38:963–74.
15. Thiébaud R, Jacqmin-Gadda H, Chêne G, Lepout C, Commenges D. Bivariate linear mixed models using SAS proc MIXED. *Comput Methods Prog Biomed*. 2002;69:249–56.
16. Ostawal A, Mocevic E, Kragh N, Xu W. Clinical effectiveness of liraglutide in type 2 diabetes treatment in the real-world setting: a systematic literature review. *Diabetes Ther*. 2016;7:411–38.
17. Gautier JF, Martinez L, Penfornis A, Eschwège E, Charpentier G, Huret B, et al. Effectiveness and persistence with liraglutide among patients with type 2 diabetes in routine clinical practice—evidence: a prospective, 2-year follow-up, observational, post-marketing study. *Adv Ther*. 2015;32:838–53.
18. Gomez-Peralta F, Abreu C, Castro JC, Alcarria E, Cruz-Bravo M, Garcia-Llorente MJ, et al. An association between liraglutide treatment and reduction in excessive daytime sleepiness in obese subjects with type 2 diabetes. *BMC Endocr Disord*. 2015;15:78.
19. Diaz-Soto G, de Luis DA, Conde-Vicente R, Izaola-Jauregui O, Ramos C, Romero E. Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study. *Diabetes Res Clin Pract*. 2014;104:92–6.
20. Mezquita-Raya P, Reyes-García R, Moreno-Perez O, Escalada-San Martín J, Ángel Rubio Herrera M, Lopez de la Torre Casares M, Clinical Effects of Liraglutide in a Real-World Setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study. *Diabetes Ther*. 2015;6:173–85.
21. Lecube A, Gonzalez C, Morales C. Liraglutida en la práctica clínica: control glucémico y predictores de buena respuesta. *Med Clín*. 2016;146:415–6.
22. Gómez-Peralta F, Lecube A, Fernández-Mariño A, Alonso-Troncoso I, Morales C, Morales-Pérez FM, et al. Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real-world retrospective study conducted in Spain. *Diabet Med*. 2018, <http://dx.doi.org/10.1111/dme.13769>.
23. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med*. 2008;359:1577–89.
24. Lindström J, Peltonen M, Eriksson JG, Ilanne-Parikka P, Aunola S, Keinänen-Kiukkaanniemi S, et al. Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS). *Diabetologia*. 2013;56:284–93.
25. Gæde P, Oellgaard J, Carstensen B, Rossing P, Lund-Andersen H, Parving HH, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. *Diabetologia*. 2016;59:2298–307.
26. de Wit HM, Vervoort GM, Jansen HJ, de Grauw WJ, de Galan BE, Tack CJ. Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT). *Diabetologia*. 2014;57:1812–9.

27. Maggard-Gibbons M, Maglione M, Livhits M, Ewing B, Maher AR, Hu J, et al. Bariatric surgery for weight loss and glycemic control in nonmorbidly obese adults with diabetes: a systematic review. *JAMA*. 2013;309:2250–61.
28. Cotugno M, Nosso G, Saldamacchia G, Vitagliano G, Griffo E, Lupoli R, et al. Clinical efficacy of bariatric surgery versus liraglutide in patients with type 2 diabetes and severe obesity: a 12-month retrospective evaluation. *Acta Diabetol*. 2015;52:331–6.
29. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2016;375:1834–44.
30. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erond N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med*. 2017;377:644–57.